<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>#022: A Map of Mitochondria Longevity Companies (PART 2) - Hex Index</title>
  <link rel="stylesheet" href="../../styles.css">
</head>
<body class="reading-mode">
  <header class="reading-header">
    <a href="../../index.html" class="back-link">&larr; Back to Library</a>
  </header>
  <main class="reading-content">
    
    <article class="article-page">
      <header class="article-header">
        <h1>#022: A Map of Mitochondria Longevity Companies (PART 2)</h1>
        <div class="article-meta">
          <span class="author">By Nathan Cheng</span>
          <span class="separator">&middot;</span>
          <a href="../../publication/longevitymarketcap/index.html" class="publication">
            Longevity Marketcap
          </a>
          <span class="separator">&middot;</span><time>Mar 3, 2021</time>
          <span class="separator">&middot;</span>
          <span class="read-time">24 min read</span>
        </div>
      </header>

      

      <div class="article-excerpt">
        <p>*This is PART 2 of <a href="https://sub.longevitymarketcap.com/p/022-mitochondria-longevity-companies">Newsletter #022: A Map of Mitochondria Longevity Companies (PART 1)</a></p><h2><strong>Peroxidation / Oxidation</strong></h2><h2><a href="https://www.stealthbt.com/">Stealth BioTherapeutics (NASDAQ:MITO)</a></h2><div id="youtube2-PjT5yt4EokI" class="youtube-wrap" data-attrs="{&quot;videoId&quot;:&quot;PjT5yt4EokI&quot;,&quot;startTime&quot;:null,&quot;endTime&quot;:null}" data-component-name="Youtube2ToDOM"><div class="youtube-inner"><iframe src="https://www.youtube-nocookie.com/embed/PjT5yt4EokI?rel=0&amp;autoplay=0&amp;showinfo=0&amp;enablejsapi=0" frameborder="0" loading="lazy" gesture="media" allow="autoplay; fullscreen" allowautoplay="true" allowfullscreen="true" width="728" height="409"></iframe></div></div><ul><li><p><strong>Market cap</strong>: $94 M</p></li><li><p><strong>Enterprise Value:</strong> $54 M</p></li><li><p><strong>Cash:</strong> $40 M&nbsp;</p></li><li><p><strong>Founded</strong>: 2006</p></li><li><p><strong>Modality</strong>: peptide, injection</p></li><li><p><strong>Founders</strong>: Hazel Szeto</p></li><li><p><strong>Partnership</strong>: <a href="https://www.businesswire.com/news/home/20191010005160/en/Alexion-and-Stealth-Announce-Agreement-for-Option-to-Co-Develop-and-Commercialize-Late-Stage-Therapy-for-Mitochondrial-Diseases">Alexion</a> (NASDAQ:ALXN)</p></li><li><p><strong>Notable Investors:&nbsp;</strong></p></li><li><p><strong>Pipeline</strong>:</p><ul><li><p>Elamipretide // Barth Syndrome (rare mitochondrial disease) //<a href="https://clinicaltrials.gov/ct2/show/NCT03098797"> Phase 2/3</a> (active)</p></li><li><p>Elamipretide // Geographic Atrophy (Dry AMD) // <a href="https://clinicaltrials.gov/ct2/show/NCT03891875?term=stealth+biotherapeutics&amp;draw=6&amp;rank=1">Phase 2</a> (recruiting)</p></li><li><p>Elamipretide // Duchenne cardiomyopathy // Phase 2 (planned 2021)&nbsp;</p></li><li><p>Elamipretide // Freidreich’s Ataxia // Phase 2 (planned 2021)</p></li><li><p>Elamipretide // Leber Hereditary Optic Neuropathy (LHON) // Phase 2 complete</p></li><li><p>2nd generation peptides &amp; mimetics // Neurodegenerative diseases // Preclinical</p></li></ul></li></ul><ul><li><p>Links</p><ul><li><p><a href="https://investor.stealthbt.com/download/companies/stealthbio/Presentations/Jan%202021%20print.pdf">Slide deck Jan 2021</a></p></li><li><p><a href="https://investor.stealthbt.com/websites/stealthbio/English/5200/us-press-release.html?airportNewsID=ad5cf79e-820f-4902-95dd-8d9c12e6d0ad">Q3 Report</a></p></li></ul></li></ul><h3>General Notes</h3><ul><li><p>Stealth BioTherapeutics is a clinical-stage company developing peptides and peptide mimetics to treat diseases linked to mitochondrial dysfunction.</p></li><li><p>Their main asset is a four-amino acid peptide called <strong>elamipretide</strong>. Elamipretide is believed to permeate the outer mitochondrial membrane where it helps reduce the production of Reactive Oxygen Species and stabilize <strong>cardiolipin, </strong>a phospholipid foundin the inner mitochondrial membrane.</p></li><li><p><strong>Stealth had a <a href="https://www.biospace.com/article/stealth-bio-s-elamipretide-flunks-mitochondrial-myopathy-trial/">high-profile failure</a> of a Phase 3 trial for elamipretide </strong>to treat Primary Mitochondrial Myopathy in December 2019. The stock fell ~66% on the news and down as much as 90% in subsequent months.</p></li><li><p>Stealth’s lead clinical program is targeting Barth Syndrome, a rare mitochondrial disease. Some early Phase 2 data has shown elamipretide improves 6-minute walking test, cardiac function biomarkers, and Barth Syndrome Scale scores.&nbsp;</p></li><li><p>Stealth is also developing 2nd generation peptides or peptide mimetics (SBT-272, SBT-550).&nbsp;</p></li></ul><h3>Origins &amp; Funding</h3><ul><li><p><strong><a href="http://ezramagazine.cornell.edu/Update/April11/EU.Szeto.profile.html">Hazel Szeto</a></strong> accidentally discovered peptides that act on mitochondria as a researcher at Weill Cornell Medical College studying opioid receptors.&nbsp;</p></li><li><p>Stealth was eventually spawned out of <strong>Morningside Ventures</strong>, a venture capital firm founded by a wealthy Hong Kong family. Rennie McCarthy, a lawyer, and Principal at Morningside would eventually be placed as CEO of Stealth.&nbsp;</p></li><li><p><a href="https://endpts.com/morningside-spawned-stealth-bios-ipo-stumbles-out-of-the-gate-raising-78m/">Morningside</a> is the majority investor in the company and has also injected cash into the company post-IPO.&nbsp;</p></li></ul><h3>Pipeline Details</h3><div class="captioned-image-container"><figure><a class="image-link image2 is-viewable-img" target="_blank" href="https://substackcdn.com/image/fetch/$s_!m6qG!,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png" data-component-name="Image2ToDOM"><div class="image2-inset"><picture><source type="image/webp" srcset="https://substackcdn.com/image/fetch/$s_!m6qG!,w_424,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 424w, https://substackcdn.com/image/fetch/$s_!m6qG!,w_848,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 848w, https://substackcdn.com/image/fetch/$s_!m6qG!,w_1272,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 1272w, https://substackcdn.com/image/fetch/$s_!m6qG!,w_1456,c_limit,f_webp,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 1456w" sizes="100vw"><img src="https://substackcdn.com/image/fetch/$s_!m6qG!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png" width="1456" height="725" data-attrs="{&quot;src&quot;:&quot;https://bucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com/public/images/e829813e-5478-49fe-969f-2da82ee24c98_1600x797.png&quot;,&quot;srcNoWatermark&quot;:null,&quot;fullscreen&quot;:null,&quot;imageSize&quot;:null,&quot;height&quot;:725,&quot;width&quot;:1456,&quot;resizeWidth&quot;:null,&quot;bytes&quot;:null,&quot;alt&quot;:null,&quot;title&quot;:null,&quot;type&quot;:null,&quot;href&quot;:null,&quot;belowTheFold&quot;:true,&quot;topImage&quot;:false,&quot;internalRedirect&quot;:null,&quot;isProcessing&quot;:false,&quot;align&quot;:null,&quot;offset&quot;:false}" class="sizing-normal" alt="" srcset="https://substackcdn.com/image/fetch/$s_!m6qG!,w_424,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 424w, https://substackcdn.com/image/fetch/$s_!m6qG!,w_848,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 848w, https://substackcdn.com/image/fetch/$s_!m6qG!,w_1272,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 1272w, https://substackcdn.com/image/fetch/$s_!m6qG!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2Fbucketeer-e05bbc84-baa3-437e-9518-adb32be77984.s3.amazonaws.com%2Fpublic%2Fimages%2Fe829813e-5478-49fe-969f-2da82ee24c98_1600x797.png 1456w" sizes="100vw" loading="lazy"></picture><div class="image-link-expand"><div class="pencraft pc-display-flex pc-gap-8 pc-reset"></div></div></div></a></figure></div><ul><li><p>Stealth has <strong>two active clinical trials with elamipretide</strong>. Most of their planned clinical trials involve elamipretide, with a couple of newer 2nd generation peptides/mimetics being tested for neurological indications</p></li><li><p><strong>Elamipretide</strong> (also known as MTP-131, SS-31, Bendavia) is a four-amino acid peptide. ~0.68 kDa weight. Stealth believes it can permeate the mitochondrial membrane, reduce the levels of Reactive Oxygen Species, and stabilize <strong>cardiolipin</strong> </p></li></ul>...</source>
      </div>

      <div class="read-full-article">
        <a href="https://sub.longevitymarketcap.com/p/022-mitochondria-longevity-companies-448" class="read-button" target="_blank" rel="noopener">
          Read full article on Longevity Marketcap &rarr;
        </a>
        <p class="copyright-note">
          This excerpt is provided for preview purposes.
          Full article content is available on the original publication.
        </p>
      </div>
    </article>
  
  </main>
</body>
</html>